期刊文献+

肺癌化疗致严重口腔溃疡1例 被引量:3

One case of severe oral ulcer due to chemotherapy treatment for lung cancer
暂未订购
导出
摘要 1例61a男性患者,因肺小细胞癌入院之前行EP(顺铂、足叶乙甙)方案化疗7个疗程,并予多次放射性治疗,治疗过程中无口腔溃疡发生。入院后给予VCM方案(甲氨蝶呤40mg、环磷酰胺1.6g、长春新碱4mg)化疗,并于化疗前始给予腺苷钴胺片、碳酸氢钠片口服。2d后患者出现咽痛及舌尖疼痛,7d后口腔溃疡逐渐加重,致使化疗中断,给予碘甘油、呋喃西林溶液、重组人表皮生长因子外用溶液(Ⅰ)、康复新液、苯扎氯铵溶液外用,20d后痊愈。 A 61-year-old male patient who was diagnosed as small cell lung cancer received EP chemotherapy regimen(cisplatin and etoposide) for 7 cycles and radiation therapy before admission.During that treatment period,the patient had no symptom of oral ulcer.Chemotherapy regimen of VCM(methotrexate 40 mg,cyclophosphamide 1.6 g and vincristine 4 mg) was applied after admission in our hospital.The cobamamide and sodium bicarbonate tablets were given before the treatment with VCM regimen.He developed sore throat and tongue pain after two days,and the symptom aggravated after 7 days,then the chemotherapy was stopped.Iodine glycerine,furacilin solution,recombinant human epidermal growth factor for external use,Kangfuxin liquid and benzalkonium chloride solution were given for external application.The patient recovered from oral ulcer after 20 days.
出处 《中国药物应用与监测》 CAS 2010年第6期386-387,共2页 Chinese Journal of Drug Application and Monitoring
关键词 肺癌 化疗 口腔溃疡 Lung cancer Chemotherapy Oral ulcer
  • 相关文献

参考文献7

二级参考文献14

共引文献69

同被引文献29

  • 1李书梅,陈璐,徐桂芝.0.3%碳酸氢钠生理盐水预防化疗患儿口腔溃疡的临床观察[J].护理实践与研究,2007,4(2):20-22. 被引量:12
  • 2Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers[J]. Ther Adv MedOncol, 2014, 6(4): 154-166.
  • 3P6pulo H, Lopes JM, Soares E The mTOR signalling pathway in human cancer[J]. Int J Mol Sci, 2012, 13(2): 1886-1918.
  • 4Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors[J]. Cancer, 2010, 116(18): 4256-4265.
  • 5Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
  • 6Motzer RJ, Barrios CH, Kim TM, et al. Phase randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2014, 32(25): 2765-2772.
  • 7Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v4.0 (CTCAE)[EB/OL]. (2013-03-20) [2014-10-20]. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm.
  • 8Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial[J]. JAMA, 2014. 312(1): 57-67.
  • 9Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6): 514-523.
  • 10Tsukamoto T, Shinohara N, Tsuchiya N, et al. Phase I~ trial of everolius in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1 [J]. Jpn J Clin Oneol, 2011, 41(I): 17-24.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部